Xiu believes that ovarian cancer is a "tyrant cancer" among gynecological tumors. It is mostly asymptomatic or mild in the early stage, and the early diagnosis rate is low. 70% of the diagnosis is advanced, and the treatment effect is poor. In addition to the need to remove the tumor tissue as much as possible to achieve no residual R0, chemotherapy is still an indispensable treatment method.
However, chemotherapy is actually as impactful to ovarian cancer patients as surgery. The reason is that chemotherapy often requires multiple times (6 times for advanced patients). In addition to nausea, vomiting, rashes, and allergies during chemotherapy, hair loss is an inevitable pain of many chemotherapy drugs.
Doxorubicin (doxorubicin) is a drug that makes oncologists in awe. The drug can inhibit the synthesis of DNA and RNA, has a wide range of anti-tumor spectrum, belongs to the cycle of non-specific drugs, and is effective in a variety of tumors. However, although doxorubicin is dazzling, its shortcomings can be described as "exceptional talent". Its cardiotoxicity often strikes back and directly knocks the patient down, so in my mind, it has always been defined as - "Lubu in people, doxorubicin in medicine", so I dare not use it easily.
However, with the development of science and technology and the improvement of drug research and development, a lipid package was applied to doxorubicin, and after pegylation technology strengthened the stability, the new drug - pegylated liposome doxorubicin (PLD), opened a new page. Through these modifications, the drug particle size is increased, it is not easy to leak out from the vascular space of normal tissues, and the stability is high, which greatly reduces cardiotoxicity and immunogenicity. At the same time, the blood drug concentration compared with its predecessor doxorubicin has made remarkable progress, allowing Lubu to be controlled and play its due benign role.
At present, pegylated liposomal doxorubicin (PLD) + carboplatin has shown the same excellent therapeutic effect as paclitaxel + carboplatin after a number of clinical comparison trials. It has now entered the first-line program of the NCCN guideline, and together with the other six programs form the "Seven Fairies" to jointly resist ovarian malignant tumors. One of the major advantages of the PLD + carboplatin program is: low hair loss rate. Everyone loves beauty, and cancer patients also love beauty and pay attention to image. Low hair loss rate is the most happy and satisfied side of patients in clinical application. Personally, I believe that while ensuring the treatment effect, we must also pay attention to maintaining the image of patients, so as to improve the quality of life and quality of life from the inside out.
When making the courseware, I relearned the relevant content of pharmacology and clinical drug trials, which benefited a lot. Thanks to Professors Lin Zhongqiu, Yao Shuzhong, He Mian and Ke Peiqi for their guidance in the production of this courseware. I also hope that more colleagues will pay attention to gynecological malignancies and contribute their own strength to the treatment of cancer patients.
